Efficacy and delivery strategies of the dual Rac/Cdc42 inhibitor MBQ-167 in HER2 overexpressing breast cancer is a research paper published in Translational Oncology (2024). On theSindex it has a DataRank of 0. It has been cited 5 times.
Scored on demand from live citation data
DataRank reads this dataset's downstream impact straight off the citation graph â no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full â never from an abstract alone.
University of Kansas
Grant: SC3GM084824
National Institutes of Health
Grant: 5P20GM103475
National Institutes of Health
Grant: 5SC3GM116713-04
Towards the Development of Novel Vav-Rac Inhibitors
National Institutes of Health
Grant: 5R25GM061838-22
NIGMS RISE Program at the UPR Medical Sciences Campus
National Institutes of Health
Grant: 5P20GM103475-16
Advancing Competitive Biomedical Research in Puerto Rico
National Institutes of Health
Grant: 5R16GM145558-04
Unraveling the Role of MMP3 in the Cisplatin Resistance of Ovarian Cancer
National Institutes of Health
Grant: 3SC3GM084824-09S1
Targeting breast cancer progression
FWCI
0.90
Citation Percentile
0.8%
Citation Trend
Fields of Study
Keywords
Sustainable Development Goals